Drug Trial Radar · NCT06801249
Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome
Last checked: Nov 20, 2026Latest source record: Jan 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Feb 23, 2021
Primary completion
Nov 30, 2024
Study completion Feb 17, 2025
Sponsor
- Lead sponsor
- IRCCS Azienda Ospedaliero-Universitaria di BolognaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Drug interventional, controlled, randomized open-label, parallel-group, multicenter study in patients with bilateral adrenal incidentalomas associated with subclinical Cushing's syndrome
Conditions
- Adrenal Incidentalomas
- Cushing Syndrome
Interventions
MetaraponeDrug
Metirapone is an inhibitor of the enzyme 11-β-adrenal hydroxylase, which is deputed to catalyze the conversion of 11-desoxycortisol (11-S) to cortisol and 11-deoxycorticosterone (DOC) to corticosterone.
Standardized antihypertensive therapyDrug
Standardized antihypertensive therapy, as provided in the normal course of care and in accordance with current European guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Number and/or Dosage of Antihypertensive Drugs at 12 Months with Metirapone Treatment, Maintaining Target Blood Pressure RangeTime frame: through study completion, an average of 2 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy · Recruiting
Azienda Ospedaliera Universitaria Federico II
Naples, Italy · Recruiting
Azienda Ospedale-Università Padova
Padova, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.